Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Feature|Articles|May 31, 2025
Examining Tominersen as a Potential Treatment for Huntington Disease: The GENERATION HD2 trial
Author(s)Isabella Ciccone, MPH
Fact checked by: Marco Meglio
The phase 2 trial tests Roche’s investigational antisense oligonucleotide therapy tominersen in patients with early stages of Huntington disease, a disease with no FDA-approved therapies available.
Advertisement
Advertisement
Huntington disease (HD) is a rare, inherited neurological condition that progressively impacts movement, cognitive abilities, and behavior. Early signs can include subtle changes in mood, thinking, and behavior, which may not immediately interfere with daily functioning. As the disease advances, individuals may experience involuntary, jerky movements that interfere with basic tasks such as walking and eating, a stage known as early manifest HD. HD is caused by a mutation in the huntingtin gene (HTT), which leads to the production of a toxic form of the huntingtin protein (mHTT).
Related to this article
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.
The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and nonmotor symptoms in Parkinson disease.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
Advertisement
Advertisement